Ryan Smith is the founder of TruDiagnostic, a CLIA-certified laboratory and health data company specializing in insights from epigenetic methylation analysis. Since 2020, TruDiagnostic has built the world’s largest private epigenetic database with more than 200,000 patients tested and has developed algorithms predicting inflammatory markers, disease risk, telomere length, aging pace, immune cell subsets, cellular replication, and other biologically relevant metrics. The company has led over 70 clinical trials investigating how diet, lifestyle, and prescription interventions can reverse adverse epigenetic markers, and collaborates with leading institutions including Duke, Harvard, Yale, and Stanford. Before TruDiagnostic, Ryan founded Tailor Made Compounding and the International Peptide Society, advancing peptide therapeutics in the U.S.

Dr. Chris D’Adamo, PhD, is an epidemiologist specializing in how modifiable lifestyle factors influence health across the lifespan and is a partner at OvationLab. He earned his Ph.D. in Epidemiology from the University of Maryland School of Medicine, where he later served as Director of Research for the Center for Integrative Medicine. As Principal Investigator, Dr. D’Adamo has led numerous clinical trials and observational studies on dietary supplements, natural products, interventional devices, micronutrients, environmental toxicants, and lifestyle-based interventions. He has authored over 100 peer-reviewed publications, contributed to medical textbooks, and lectures internationally on nutrition and integrative medicine. Dr. D’Adamo also serves as Senior Research Advisor to the Institute for Functional Medicine and sits on several scientific advisory boards.

Tom Blue is a Founding Partner of OvationLab, a business advisory and clinical research firm that helps companies in natural products, testing, digital health, and medical devices successfully launch and commercialize within the healthcare professional channel. Since establishing Virginia’s first concierge medical practice in 2001, he has focused on designing and implementing innovative practice models that accelerate the translation of emerging best practices into real-world care. His latest venture, AndHealth—a root-cause, largely virtual clinical model backed in part by the AMA’s investment arm—closed the largest seed round in digital health in 2021 at $57M. Tom’s current work centers on the rapidly evolving longevity marketplace, clinical application